<?xml version="1.0" encoding="UTF-8"?>
<p>The traditional clinical trial phases require significant investment and resources to be executed, and the lengthy nature of the process could itself be described as a bottleneck. Many EIDs are prone to sporadic outbreaks in which morbidity and mortality are high, and it is sometimes not possible to conduct traditional phase III efficacy trials due to ethical considerations and the scale and unpredictable nature of EID outbreaks [
 <xref ref-type="bibr" rid="CR18">18</xref>]. To meet the unique challenges of vaccine development for EIDs, an innovative, efficient global system of vaccine research and development (R&amp;D) for EIDs is needed [
 <xref ref-type="bibr" rid="CR10">10</xref>].
</p>
